Evidence map›Paper›PMID 40692505›Full record

SynthesisTropical medicine & international health : TM & IH2025

Burden of Chikungunya Fever and Its Economic and Social Impacts Worldwide: A Systematic Review.

Vaneide Daciane Pedí, Giovanny Vinícius Araújo de França, Viviane Bellini Rodrigues, Felipe Tavares Duailibe, Marcella T P Santos, Maria Regina Fernandes de Oliveira

Abstract readSystematic Review
In one paragraph

Synthesis in Tropical medicine & international health : TM & IH, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Climate change and budget cuts: Facing theMalariaWorld journal · 2026
    Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Vaneide Daciane PedíFundação Oswaldo Cruz, Brasília, Federal District, Brazil.ORCID https://orcid.org/0000-0003-4294-7238
Giovanny Vinícius Araújo de FrançaMinistério da Saúde do Brasil, Secretaria de Ciência, Tecnologia e Inovação e do Complexo Econômico Industrial da Saúde, Departamento de Ciência de Tecnologia, Brasília, Federal District, Brazil.ORCID https://orcid.org/0000-0002-7530-2017
Viviane Bellini RodriguesDepartamento de Nutrição, Universidade de Brasília, Brasília, Federal District, Brazil.ORCID https://orcid.org/0000-0002-2389-820X
Felipe Tavares DuailibeBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.ORCID https://orcid.org/0000-0001-5218-8103
Marcella T P SantosCentro Universitário de Brasília, Brasília, Federal District, Brazil.ORCID https://orcid.org/0009-0003-8224-6038
Maria Regina Fernandes de OliveiraFaculdade de Medicina, Programa de Pós-Graduação em Medicina Tropical, Universidade de Brasília, Brasília, Federal District, Brazil.ORCID https://orcid.org/0000-0002-4995-2526

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis study aimed to investigate the social and economic impacts and disease burden of Chikungunya Fever globally through a systematic literature review.

methodsWe performed a comprehensive literature search through MEDLINE (via PubMed), LILACS, and Embase databases, and grey literature, including studies of populations diagnosed with Chikungunya Fever or at risk of infection published in English, Spanish, French, or Portuguese, without date restrictions. Two reviewers independently performed study selection, data extraction, and quality assessment. Methodological quality was assessed using different tools.

resultsForty-three publications were included. Until 2013, publications originated solely from the Asian and African continents. From 2015 onwards, South America emerged as the predominant source. Publications were classified as cost studies (25), including cost-of-illness (18) and program cost (6); burden of disease studies (10); cost-outcome studies (4), including cost-effectiveness (3) and cost-utility (1); and quality-of-life studies (15). Reported total direct costs associated with Chikungunya Fever ranged from US$ 3.5 million (US Virgin Islands, 2014-2015) to US$ 83.6 billion (Region of the Americas, 2013-2015). Direct medical costs varied from US$ 308.94 (Tamil Nadu, India, 2006) to US$ 33.7 million (Réunion Island, 2005-2006). Vector control program costs ranged from US$ 888,000 annually (Greece, 2013-2017) to US$ 466 million (Brazil, 2016). Estimated disability-adjusted life years per 100,000 population ranged from 4.53 (India, 2006) to 2432 (Region of the Americas, 2013-2015). Quality-of-life studies demonstrated substantial declines across multiple domains, indicating significant functional impairment due to Chikungunya Fever.

conclusionChikungunya Fever imposes a considerable economic and social burden, surpassing that of other endemic arboviral diseases such as dengue and yellow fever. These findings underscore the need for further research to accurately quantify the full scope of Chikungunya Fever-related costs and impacts on affected populations.

Indexed as

Chikungunya FeverCost of IllnessGlobal HealthCost-Benefit AnalysisHealth Care CostsHumansQuality of Lifeburden of diseaseChikungunyadisability‐adjusted life yearsdisease costseconomic and social impacteconomic studiesquality of lifesystematic review

Identifiers

PMID40692505
PMCPMC12401649

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.